Kalaris Therapeutics Inc. (NASDAQ:KLRS) Stock Rated "Moderate Buy" by Wall Street Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Kalaris Therapeutics, with six buy ratings and one sell rating. The average 12-month price target is $18.75.
• KLRS shares opened at $3.07, down 1.6%, near their 12-month low of $3.02 and well below the 12-month high of $11.88. The company has a market capitalization of approximately $73.1 million.
• Institutional investors and hedge funds own 66.05% of the stock, while Kalaris reported a quarterly loss of $0.48 per share—beating estimates by $0.02. The clinical-stage biotech is developing treatments for retinal vascular diseases and other serious eye disorders.

Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $18.75.

Several research firms recently commented on KLRS. Wall Street Zen lowered Kalaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, September 13th. TD Cowen began coverage on shares of Kalaris Therapeutics in a research report on Monday, June 15th. They issued a "buy" rating for the company. Finally, Weiss Ratings lowered shares of Kalaris Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, July 28th.

Institutional Investors Weigh In On Kalaris Therapeutics

A number of large investors have recently added to or reduced their stakes in KLRS. ADAR1 Capital Management LLC acquired a new stake in Kalaris Therapeutics during the 2nd quarter valued at approximately $407,000. Simplify Asset Management Inc. raised its position in shares of Kalaris Therapeutics by 335.5% in the 1st quarter. Simplify Asset Management Inc. now owns 87,426 shares of the company's stock valued at $504,000 after purchasing an additional 67,352 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Kalaris Therapeutics in the 2nd quarter valued at approximately $222,000. Propel Bio Management LLC purchased a new position in shares of Kalaris Therapeutics during the 4th quarter valued at approximately $355,000. Finally, Pale Fire Capital SE purchased a new position in shares of Kalaris Therapeutics during the 2nd quarter valued at approximately $161,000. 66.05% of the stock is owned by institutional investors and hedge funds.

Kalaris Therapeutics Trading Down 1.6%

Shares of NASDAQ KLRS opened at $3.07 on Friday. The stock has a fifty day moving average price of $3.78 and a 200 day moving average price of $4.91. Kalaris Therapeutics has a 12-month low of $3.02 and a 12-month high of $11.88. The company has a market cap of $73.10 million, a P/E ratio of -1.52 and a beta of 0.22.

Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.02. On average, sell-side analysts forecast that Kalaris Therapeutics will post -1.99 EPS for the current fiscal year.

Kalaris Therapeutics Company Profile

Kalaris Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for retinal vascular diseases and other serious eye disorders. Its research programs are aimed at addressing diseases in which abnormal blood-vessel growth or leakage can impair vision.

The company's activities include the discovery and clinical development of investigational ophthalmic medicines intended to improve outcomes for patients with retinal conditions. Kalaris Therapeutics has not yet established a broad portfolio of marketed products, and its principal programs remain in development.

Publicly available information about the company's broader operating history, geographic reach and leadership is limited.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.